PIC Therapeutics is a biotechnology company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation.
PIC Therapeutics was founded on the seminal work of Dr. Gerhard Wagner, a professor at Harvard Medical School world-renowned for his scientific expertise in protein structure and his research on interactions of eukaryotic translation initiation factors (eIFs).
PIC Therapeutics, led by President and CEO Dr. Kathy Bowdish, was launched to translate these discoveries into small molecule precision therapeutics to benefit cancer patients.
Our precision-based therapeutics target the “master switch” of cancer signaling pathways, selectively blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. Our selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.
PIC Therapeutics was founded on the seminal work of Dr. Gerhard Wagner, a professor at Harvard Medical School world-renowned for his scientific expertise in protein structure and his research on interactions of eukaryotic translation initiation factors (eIFs).
PIC Therapeutics, led by President and CEO Dr. Kathy Bowdish, was launched to translate these discoveries into small molecule precision therapeutics to benefit cancer patients.
Our precision-based therapeutics target the “master switch” of cancer signaling pathways, selectively blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. Our selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.
Location: United States, Massachusetts, Natick
Employees: 11-50
Total raised: $40M
Founded date: 2016
Investors 3
| Date | Name | Website |
| 28.10.2022 | Lumira Ven... | lumiravent... |
| 30.08.2023 | OrbiMed | orbimed.co... |
| - | Advent Lif... | adventls.c... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.10.2022 | Series A | $35M | - |
| 15.04.2020 | Seed | $5M | - |
Mentions in press and media 9
| Date | Title | Description |
| 20.10.2022 | PIC Therapeutics Closes $35M Series A Financing | PIC Therapeutics, a Natick, MA-based biopharmaceutical company, raised $35M in Series A funding. The round was led by OrbiMed with participation from Lumira Ventures, Harrington Discovery Institute, Advent Life Sciences and Belinda Termeer.... |
| 19.10.2022 | PIC Therapeutics Inks $35M Series A Financing | NATICK, MA, PIC Therapeutics, announced the closing of a $35 million Series A financing led by OrbiMed. >> Click here for more funding data on PIC Therapeutics >> To export PIC Therapeutics funding data to PDF and Excel, cli... |
| 19.10.2022 | Lumira Ventures Participates In The Closing of PIC Therapeutics $35 Million Series A Financing to Develop Treatments for Drug-Resistant Breast Cancer | October 19, 2022 – PIC Therapeutics, Inc., a biopharmaceutical company dedicated to developing life-changing medicines for patients with cancer, today announced the closing of a $35 million Series A financing led by OrbiMed. Other new inves... |
| 19.10.2022 | PIC Therapeutics Completes $35 Million Series A Financing to Develop Treatments for Drug-Resistant Breast Cancer | - |
| 15.04.2020 | PIC Therapeutics Raises $5 Million | BOSTON--(BUSINESS WIRE)--PIC Therapeutics, a biotechnology company focused on transforming the treatment of cancer though the selective modulation of oncogene translation, closed a $5M Series Seed round of preferred equity funding. The over... |
| 15.04.2020 | PIC Therapeutics Raises $5M in Seed Funding | PIC Therapeutics, a Boston, MA-based biotechnology company focused on transforming the treatment of cancer though the selective modulation of oncogene translation, closed a $5M seed equity funding. The round was led by Advent Life Sciences ... |
| 15.04.2020 | PIC Therapeutics Raises $5 Million | BOSTON--(BUSINESS WIRE)--PIC Therapeutics, a biotechnology company focused on transforming the treatment of cancer though the selective modulation of oncogene translation, closed a $5M Series Seed round of preferred equity funding. The over... |
| 15.04.2020 | PIC Therapeutics Picks Up $5M Seed Funding | BOSTON, MA, PIC Therapeutics has closed a $5M Series Seed round of preferred equity funding. >> Click here for more funding data on PIC Therapeutics >> To export PIC Therapeutics funding data to PDF and Excel, click here ... |
| - | PIC Therapeutics | “Cancer Research | PIC Therapeutics | mRNA” |